Quantitative TP53 circulating tumor DNA predicts tumor response and survival outcomes in esophageal squamous cell carcinoma

Figure 2 Dynamics of TP53 circulating tumor DNA variant allele frequency in esophageal squamous cell carcinoma patients. A: Postoperative TP53 ctDNA variant allele frequency was significantly reduced compared to preoperative levels; B: In the neoadjuvant chemotherapy (NCT) subgroup, no significant differences were observed in TP53 ctDNA levels across treatment timepoints (pre-NCT vs post-NCT vs post-surgery); ctDNA not detected: Shown as 0.01% on log scale. VAF: Variant allele frequency; ctDNA: Circulating tumor DNA.